26 related articles for article (PubMed ID: 16650985)
1. Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations.
Marton J; Fekete A; Cumming P; Hosztafi S; Mikecz P; Henriksen G
Molecules; 2022 Apr; 27(9):. PubMed ID: 35566212
[TBL] [Abstract][Full Text] [Related]
2. Electrochemical
Glotz G; Kappe CO; Cantillo D
Org Lett; 2020 Sep; 22(17):6891-6896. PubMed ID: 32790319
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of morphine tolerance and dependence by thymoquinone in mice.
Hosseinzadeh H; Parvardeh S; Masoudi A; Moghimi M; Mahboobifard F
Avicenna J Phytomed; 2016; 6(1):55-66. PubMed ID: 27247922
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological mechanisms underlying the antinociceptive and tolerance effects of the 6,14-bridged oripavine compound 030418.
Wen Q; Yu G; Li YL; Yan LD; Gong ZH
Acta Pharmacol Sin; 2011 Oct; 32(10):1215-24. PubMed ID: 21863064
[TBL] [Abstract][Full Text] [Related]
5. Search for the "ideal analgesic" in pain treatment by engineering the mu-opioid receptor.
Tao PL; Law PY; Loh HH
IUBMB Life; 2010 Feb; 62(2):103-11. PubMed ID: 20039371
[TBL] [Abstract][Full Text] [Related]
6. The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Patkar KA; Murray TF; Aldrich JV
J Med Chem; 2009 Nov; 52(21):6814-21. PubMed ID: 19807094
[TBL] [Abstract][Full Text] [Related]
7. Depletion of serotonin decreases the effects of the kappa-opioid receptor agonist U-69593 on cocaine-stimulated activity.
Zakharova E; Collins SL; Aberg M; Kumar A; Fernandez JB; Izenwasser S
Eur J Pharmacol; 2008 May; 586(1-3):123-9. PubMed ID: 18395712
[TBL] [Abstract][Full Text] [Related]
8. Endogenous opiates and behavior: 2006.
Bodnar RJ
Peptides; 2007 Dec; 28(12):2435-513. PubMed ID: 17949854
[TBL] [Abstract][Full Text] [Related]
9. [Opioid receptors and their selective ligands].
Piestrzeniewicz MK; Fichna J; Janecka A
Postepy Biochem; 2006; 52(3):313-9. PubMed ID: 17201067
[TBL] [Abstract][Full Text] [Related]
10. A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
Park HS; Lee HY; Kim YH; Park JK; Zvartau EE; Lee H
Bioorg Med Chem Lett; 2006 Jul; 16(13):3609-13. PubMed ID: 16650985
[TBL] [Abstract][Full Text] [Related]
11. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
12. Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine.
Yu G; Yue YJ; Cui MX; Gong ZH
J Pharmacol Exp Ther; 2006 Jul; 318(1):282-7. PubMed ID: 16569757
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine: new pharmacological aspects.
Cowan A
Int J Clin Pract Suppl; 2003 Feb; (133):3-8; discussion 23-4. PubMed ID: 12665117
[TBL] [Abstract][Full Text] [Related]
14. Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists.
Tuthill PA; Seida PR; Barker W; Cassel JA; Belanger S; DeHaven RN; Koblish M; Gottshall SL; Little PJ; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2004 Nov; 14(22):5693-7. PubMed ID: 15482950
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
